Relationship between metformin and abdominal aortic aneurysm.
Abdominal aortic aneurysm
Antidiabetic drug
Biguanide
Clinical trial
Metformin
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
21
04
2019
accepted:
20
08
2019
pubmed:
16
11
2019
medline:
30
7
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
Abdominal aortic aneurysm (AAA) is a life-threatening disease and pharmacologic agents to treat the disease remain lacking for clinical practice. Epidemiologic studies have highlighted a negative association between the use of antidiabetic drugs, including metformin, and AAA. Metformin is well-known for its blood glucose-lowering effect, but its action on both metabolism and inflammatory response has led to propose it as a potential therapeutic target in several cardiovascular diseases. In this review, we summarize the current knowledge on the link between metformin and AAA. Based on the known effects of the drug on the aortic wall, translational applications and clinical trials investigating the interest of metformin in the management of patients with AAA are discussed.
Identifiants
pubmed: 31727461
pii: S0741-5214(19)32357-2
doi: 10.1016/j.jvs.2019.08.270
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Metformin
9100L32L2N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1056-1062Informations de copyright
Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.